CurrentCignaPolicy CNF602

Phenylketonuria – Palynziq Prior Authorization Policy - (CNF602)

Defines prior authorization, clinical coverage criteria, approval durations, prescribing specialist requirement, continuation criteria, dose guidance reference, and exclusions for Palynziq (pegvaliase-pqpz) for treatment of phenylketonuria (PKU) across Cigna-administered health benefit plans.

Policy Summary

PayerCigna

PolicyPhenylketonuria – Palynziq Prior Authorization Policy - (CNF602)

Policy CodePolicy CNF602

Change TypeSelected revisions and annual updates

Effective Date

Next Review Date

Key ActionPrior authorization is recommended for Palynziq and it must be prescribed by or in consultation with a metabolic disease specialist; approvals are provided for 1 year with required baseline and response documentation.

SourceLink

POLICY UPDATE CHANGES

Age requirement was changed to ≥ 12 years of age for Initial Therapy and continuing therapy criteria.

Added Zelvysia and Sephience as examples of sapropterin/sepiapterin products in the treatment modality note.

Annual revisions noted with no criteria changes for some review dates (08/23/2023, 08/28/2024, 08/06/2025).

1Covered Indication (PKU)

>=12Minimum age requirement

>600 µmol/LUncontrolled Phe threshold

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Summary

Coverage stance: Covered with criteria for Palynziq (pegvaliase-pqpz) for phenylketonuria (PKU) per policy CNF602. Scope: Defines prior authorization, clinical coverage criteria, approval durations, prescribing specialist requirement, continuation criteria, dose guidance reference, and exclusions for Palynziq across Cigna-administered health benefit plans. Approvals for both initial and continuation therapy are for 1 year. Treatment is approved for patients aged ≥ 12 years. Baseline blood phenylalanine (Phe) must be obtained prior to initiating therapy, and Palynziq is available only through a restricted REMS program due to anaphylaxis risk. Dose titration and maintenance dosing guidance are provided per the prescribing information.

Initial Therapy Criteria

FDA-Approved Indication - Phenylketonuria

Approve for the duration noted if the patient meets ONE of the following (A or B):

A) Initial Therapy (approve for 1 year)

Patient is ≥ 12 years of age
Patient has uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on at least one existing treatment modality> 600 micromol/L
Examples of treatment modalities include restriction of dietary phenylalanine and protein intake and prior treatment with sapropterin (Kuvan, Javygtor, Zelvysia, generic) or Sephience.
Medication is prescribed by or in consultation with a metabolic disease specialist (or specialist who focuses in the treatment of metabolic diseases)

Continuation Therapy Criteria

Unproven / Exclusions

Conditions Not Covered

Palynziq (pegvaliase-pqpz) is considered not medically necessary for ANY other use(s)

Provider Actions

Prior Authorization

Prior authorization required

Prior authorization is recommended for prescription benefit coverage of Palynziq; approvals provided for durations noted (initial and continuation approvals for 1 year).

Approval duration: 1 year (initial and continuation)

Documentation Required

Specialist prescribing requirement

Palynziq must be prescribed by or in consultation with a metabolic disease specialist (or specialist focusing in treatment of metabolic diseases).

Documentation Required

Baseline and response labs

Baseline blood phenylalanine concentrations should be obtained before initiating treatment; continuation approvals require documented response as specified (≤ 600 µmol/L or ≥ 20% reduction from baseline) or documentation of continuing titration.

Applicable Codes

DrugNDCCovered

No codes listed

Clinical Evidence & References

Evidence: Prescribing information — Palynziq prescribing information, BioMarin, February 2026.

Guidelines: ACMG 2023 guidance (American College of Medical Genetics and Genomics) referenced for PKU management and Phe targets.

Guidelines: European 2025 guidelines referenced for PKU diagnosis and management and recommendations regarding Palynziq.

Safety: The policy and prescribing information note the REMS program and risk of anaphylaxis, requiring restricted distribution and management.

Additional: Dose titration and maintenance dosing schedules and recommendations are provided in the prescribing information and policy dose titration section.

Background

Background: Palynziq (pegvaliase-pqpz) is a phenylalanine‑metabolizing enzyme therapy indicated to reduce blood phenylalanine concentrations in patients with PKU. Baseline blood Phe should be obtained before initiating treatment. Because of the risk of anaphylaxis, Palynziq is available only through a restricted REMS program. The prescribing information provides dose titration guidance starting with induction and stepwise titration to a maintenance dose (targeting ≤ 600 micromol/L), with specified durations at 20 mg QD for ≥24 weeks, 40 mg QD for ≥16 weeks, and maximum 60 mg QD with discontinuation recommendations if adequate response is not achieved after the specified durations.

Revision History

10/29/2025clarified

Age requirement changed to ≥ 12 years of age for Initial Therapy and continuing therapy criteria.

03/11/2026revisedLatest

Added and clarified prescriber statement to 'according to the prescriber, the patient is continuing to titrate Palynziq to a stable maintenance dose' and added Zelvysia and Sephience as examples of sapropterin/sepiapterin products in treatment modality notes.

08/23/2023